Pulmatrix, Inc. (PULM): Price and Financial Metrics


Pulmatrix, Inc. (PULM): $0.87

0.04 (+5.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PULM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

PULM POWR Grades


  • Sentiment is the dimension where PULM ranks best; there it ranks ahead of 91.83% of US stocks.
  • PULM's strongest trending metric is Momentum; it's been moving down over the last 206 days.
  • PULM's current lowest rank is in the Stability metric (where it is better than 5.86% of US stocks).

PULM Stock Summary

  • PULM has a market capitalization of $46,742,971 -- more than approximately just 9.74% of US stocks.
  • With a year-over-year growth in debt of 186.69%, Pulmatrix Inc's debt growth rate surpasses 93.89% of about US stocks.
  • Pulmatrix Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -124.09%, greater than the shareholder yield of only 2.12% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Pulmatrix Inc, a group of peers worth examining would be ARPO, SPRO, XCUR, ACIU, and GEOS.
  • PULM's SEC filings can be seen here. And to visit Pulmatrix Inc's official web site, go to www.pulmatrix.com.

PULM Price Target

For more insight on analysts targets of PULM, see our PULM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.00 Average Broker Recommendation 1.5 (Moderate Buy)

PULM Stock Price Chart Interactive Chart >

Price chart for PULM

PULM Price/Volume Stats

Current price $0.87 52-week high $3.04
Prev. close $0.83 52-week low $0.82
Day low $0.84 Volume 1,360,000
Day high $0.92 Avg. volume 2,164,972
50-day MA $1.17 Dividend yield N/A
200-day MA $1.27 Market Cap 49.10M

Pulmatrix, Inc. (PULM) Company Bio


Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The company was founded in 2003 and is based in Lexington, Massachusetts.


PULM Latest News Stream


Event/Time News Detail
Loading, please wait...

PULM Latest Social Stream


Loading social stream, please wait...

View Full PULM Social Stream

Latest PULM News From Around the Web

Below are the latest news stories about Pulmatrix Inc that investors may wish to consider to help them evaluate PULM as an investment opportunity.

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its first quarter 2021 financial results and provides a business update.

Yahoo | May 11, 2021

Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it will host a key opinion leader (KOL) webinar on PUR3100, Pulmatrix's orally inhaled dihydroergotamine (DHE) therapy for the treatment of acute migraine, on Friday, April 23, 2021 at 10:00am Eastern Time.

Yahoo | April 15, 2021

Pulmatrix Will Regain Full Rights To PUR1800 After Termination Of Licensing Agreement; Shares Fall 16%

Pulmatrix is poised to regain full rights to its narrow spectrum kinase inhibitor (NSKI), including PUR1800. Johnson & Johnson Enterprise Innovation, a subsidiary of Johnson & Johnson, terminated Pulmatrix's license, development and commercialization agreement sending Pulmatrix shares down 16%. Pulmatrix (PULM) intends to continue developing PUR1800 and according to Chief Executive Officer, Ted Raad, regaining full rights should allow the company to advance assets that can address blockbuster markets. The company has already completed a 28-day toxicology study that showed dose-proportional systematic exposure of PUR1800 reduced lung drug accumulation potential.

Neha Gupta on TipRanks | April 13, 2021

Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio

LEXINGTON, Mass. , April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM ), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced it will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson's Enterprise Innovation's decision to terminate the Company's license, development and commercialization agreement. Pulmatrix intends to continue the development of PUR1800, with ongoing clinical and toxicology studies to support programs in acute exacerbations in COPD (AECOPD) and other chronic airway diseases. Updated PUR1800 Program Guidance: 28-day toxicology studies are complete,...

Benzinga | April 12, 2021

Pulmatrix Stock Is Trading Lower After JNJ's Lung Cancer Initiative Terminates PUR1800 Licensing Pact

Pulmatrix Inc (NASDAQ: PULM ) will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson's (NYSE: JNJ ) Enterprise Innovation's decision to terminate the license agreement. Pulmatrix intends to continue developing PUR1800 with ongoing clinical and toxicology … Full story available on Benzinga.com

Benzinga | April 12, 2021

Read More 'PULM' Stories Here

PULM Price Returns

1-mo -7.01%
3-mo -56.93%
6-mo -20.91%
1-year -42.76%
3-year -80.92%
5-year -95.95%
YTD -26.89%
2020 38.37%
2019 -64.17%
2018 -82.98%
2017 138.98%
2016 -85.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7673 seconds.